Investigating treatment targets for gammaherpesvirus infections
Therapeutic targets in gammaherpesvirus infection
This study is looking at how certain viruses can affect people with weakened immune systems, like those with AIDS, and it’s testing how vaccines might help the body fight these viruses better, all using mice to learn more about potential new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11078667 on NIH RePORTER |
What this research studies
This research focuses on understanding how gammaherpesviruses, which can cause serious health issues in individuals with weakened immune systems, affect the body over time. It uses a mouse model to study the infection process, including how vaccination may change the way the virus behaves and how the immune system responds. By examining the interactions between the virus and the immune system, the research aims to identify potential therapeutic targets that could lead to better treatments for patients with conditions like AIDS-related cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with weakened immune systems, such as those living with HIV/AIDS or undergoing immunosuppressive treatments.
Not a fit: Patients with healthy immune systems or those not infected with gammaherpesviruses may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients suffering from gammaherpesvirus-related diseases, particularly those with compromised immune systems.
How similar studies have performed: Previous research has shown promise in understanding viral infections and immune responses, but this specific approach to gammaherpesvirus treatment is relatively novel.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Van Dyk, Linda F. — University of Colorado Denver
- Study coordinator: Van Dyk, Linda F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.